- Home
- ONCY vs RAND Comparison
ONCY vs RAND Comparison
Compare ONCY & RAND Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ONCY
- RAND
- Stock Information
- Founded
- ONCY 1998
- RAND 1969
- Country
- ONCY Canada
- RAND United States
- Employees
- ONCY N/A
- RAND N/A
- Industry
- ONCY Pharmaceuticals and Biotechnology
- RAND Finance: Consumer Services
- Sector
- ONCY Health Care
- RAND Finance
- Exchange
- ONCY Nasdaq
- RAND Nasdaq
- Market Cap
- ONCY 49.1M
- RAND 52.9M
- IPO Year
- ONCY 1999
- RAND N/A
- Fundamental
- Price
- ONCY $0.52
- RAND $18.22
- Analyst Decision
- ONCY Strong Buy
- RAND
- Analyst Count
- ONCY 3
- RAND 0
- Target Price
- ONCY $4.33
- RAND N/A
- AVG Volume (30 Days)
- ONCY 333.0K
- RAND 5.4K
- Earning Date
- ONCY 05-14-2025
- RAND 05-05-2025
- Dividend Yield
- ONCY N/A
- RAND 6.37%
- EPS Growth
- ONCY N/A
- RAND 39.63
- EPS
- ONCY N/A
- RAND 3.11
- Revenue
- ONCY N/A
- RAND $8,499,970.00
- Revenue This Year
- ONCY N/A
- RAND N/A
- Revenue Next Year
- ONCY N/A
- RAND N/A
- P/E Ratio
- ONCY N/A
- RAND $5.86
- Revenue Growth
- ONCY N/A
- RAND 12.52
- 52 Week Low
- ONCY $0.47
- RAND $13.94
- 52 Week High
- ONCY $1.53
- RAND $31.89
- Technical
- Relative Strength Index (RSI)
- ONCY 41.53
- RAND 42.12
- Support Level
- ONCY $0.54
- RAND $18.00
- Resistance Level
- ONCY $0.65
- RAND $19.70
- Average True Range (ATR)
- ONCY 0.04
- RAND 0.79
- MACD
- ONCY -0.00
- RAND -0.02
- Stochastic Oscillator
- ONCY 13.36
- RAND 7.46
About ONCY Oncolytics Biotech Inc.
Oncolytics Biotech Inc is a clinical-stage biopharmaceutical company. The company is focused on the discovery and development of pharmaceutical products for the treatment of cancers that have not been treated with therapeutics. It is developing pelareorep, an immunotherapeutic agent that improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The other projects in the company's pipeline include Bracelet-1 for the treatment of Breast Cancer, Goblet cohort-1, and Goblet cohort-5 for the treatment of Gastro-Intestinal Cancer among others.
About RAND Rand Capital Corporation
Rand Capital Corp is a closed-end, externally managed, non-diversified investment company. The company's investment objective is to generate current income and, when possible, complement its current income with capital appreciation by focusing its debt and related equity investments in privately-held, lower middle market companies with committed and experienced managements in a broad variety of industries. It predominantly invests in higher-yielding debt instruments.